{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:55:54Z","timestamp":1753890954778,"version":"3.41.2"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background and aims<\/jats:title><jats:p>Progress in cardiology has extended the lifespan of patients with congenital heart defects (CHD). Cyanotic patients are exposed to typical diseases of adulthood, including atherosclerosis. Rheological changes typical of cyanosis affect the vascular endothelium's function and may promote atherosclerosis development. We assessed the endothelial function and its relationship to biochemical parameters, particularly sphingosine-1-phosphate, in cyanotic CHD patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>A cross-sectional study including 36 adult CHD cyanotic patients [(12 males) (39 median, 19\u201373 years)] with arterial blood oxygen saturation less than 92% and 30 healthy controls [(11 males) (38.5 median, 26\u201359 years)] was performed. All patients underwent clinical examination, blood sampling, and ultrasonography, during which endothelial function was assessed using intima-media thickness (IMT) and flow-mediated dilatation (FMD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We did not demonstrate any difference between CHD patients and the control group in the IMT complex and FMD. Patients with cyanosis are characterized by higher S1P serum levels (<jats:italic>p<\/jats:italic>\u2009=\u20090.04), lower ApoM (<jats:italic>p<\/jats:italic>\u2009=\u20090.04), and HDL concentrations (<jats:italic>p<\/jats:italic>\u2009=\u20090.02). Only FMD correlated positively with HDL cholesterol (<jats:italic>p<\/jats:italic>\u2009=\u20090.02) concentration. The IMT complex correlates positively only with BMI (<jats:italic>p<\/jats:italic>\u2009=\u20090.04). No factor was statistically significant in the multiple logistic regression model for FMD &amp;lt;6.5%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The values of the analyzed biochemical and clinical factors (except for the reduced HDL fraction), the lack of inflammatory factor activity, and the increased S1P concentration indicate the dominance of antiatherosclerotic activity in this population. FMD and IMT are preserved, which suggests that the risk of early atherosclerotic changes in this group is comparable to the remaining population.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2025.1531136","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T05:30:33Z","timestamp":1745818233000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Can we know more about atherosclerosis in cyanotic patients with congenital heart disease\u2014the potential role of sphingosine-1-phosphate?"],"prefix":"10.3389","volume":"12","author":[{"given":"Sonia Alicja","family":"Nartowicz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcin","family":"Gabriel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Janus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Artur","family":"Cie\u015blewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Malesza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Bartczak-Rutkowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej","family":"Lesiak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Trojnarska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"100035","DOI":"10.1016\/j.jacadv.2022.100035","article-title":"Atherosclerosis in congenital heart disease: let\u2019s not miss the forest for the trees","volume":"1","author":"Giannakoulas","year":"2022","journal-title":"JACC Adv"},{"key":"B2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ijcard.2004.08.018","article-title":"The coronary circulation in cyanotic congenital heart disease","volume":"97","author":"Perloff","year":"2004","journal-title":"Int J Cardiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"160","DOI":"10.4103\/0974-2069.99619","article-title":"Endothelial dysfunction and atherosclerosis in children with irreversible pulmonary hypertension due to congenital heart disease","volume":"5","author":"Ciftel","year":"2012","journal-title":"Ann Pediatr Cardiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jjcc.2016.09.003","article-title":"Arterial stiffness and arterial function in adult cyanotic patients with congenital heart disease","volume":"70","author":"Trojnarska","year":"2017","journal-title":"J Cardiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1253\/circj.cj-09-0858","article-title":"Atherosclerosis in patients with cyanotic congenital heart disease","volume":"74","author":"Duffels","year":"2010","journal-title":"Circ J Off J Jpn Circ Soc"},{"key":"B6","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.amjcard.2005.03.060","article-title":"Cyanotic congenital heart disease and coronary artery atherogenesis","volume":"96","author":"Fyfe","year":"2005","journal-title":"Am J Cardiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/heartjnl-2016-311012","article-title":"Cyanotic congenital heart disease and atherosclerosis","volume":"103","author":"Tarp","year":"2017","journal-title":"Heart Br Card Soc"},{"key":"B8","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s00246-009-9489-z","article-title":"Preserved flow-mediated dilation in adults with cyanotic congenital heart disease","volume":"30","author":"Pedersen","year":"2009","journal-title":"Pediatr Cardiol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/j.amjcard.2009.01.353","article-title":"Burden of coronary artery disease in adults with congenital heart disease and its relation to congenital and traditional heart risk factors","volume":"103","author":"Giannakoulas","year":"2009","journal-title":"Am J Cardiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ijcard.2018.08.104","article-title":"Subclinical atherosclerosis in patients with cyanotic congenital heart disease","volume":"277","author":"Tarp","year":"2019","journal-title":"Int J Cardiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1080\/10715762.2023.2284639","article-title":"Elevated oxidative stress in patients with congenital heart disease and the effect of cyanosis: a meta-analysis","volume":"57","author":"Vanreusel","year":"2023","journal-title":"Free Radic Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"101359","DOI":"10.1016\/j.jacadv.2024.101359","article-title":"Atherosclerotic risk factor prevalence in adults with congenital heart disease: a meta-analysis","volume":"3","author":"Papazoglou","year":"2024","journal-title":"JACC Adv"},{"key":"B13","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/S0140-6736(13)61752-3","article-title":"The Framingham heart study and the epidemiology of cardiovascular diseases: a historical perspective","volume":"383","author":"Mahmood","year":"2014","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1093\/eurheartj\/ehz350","article-title":"Expert consensus and evidence-based recommendations for the assessment of flow-mediated dilation in humans","volume":"40","author":"Thijssen","year":"2019","journal-title":"Eur Heart J"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.3390\/cells13171494","article-title":"E-Selectin and asymmetric dimethylarginine levels in adult cyanotic congenital heart disease: their relation to biochemical parameters, vascular function, and clinical Status","volume":"13","author":"Nartowicz","year":"2024","journal-title":"Cells"},{"key":"B16","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1093\/cvr\/cvac095","article-title":"Flow-mediated dilation reference values for evaluation of endothelial function and cardiovascular health","volume":"119","author":"Heiss","year":"2023","journal-title":"Cardiovasc Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.hfc.2023.12.008","article-title":"Failing with cyanosis-heart failure in end-stage unrepaired or partially palliated congenital heart disease","volume":"20","author":"Aldweib","year":"2024","journal-title":"Heart Fail Clin"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1161\/CIRCULATIONAHA.105.534073","article-title":"Systemic endothelial dysfunction in adults with cyanotic congenital heart disease","volume":"112","author":"Oechslin","year":"2005","journal-title":"Circulation"},{"key":"B19","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1017\/S1047951114000262","article-title":"Widespread endotheliopathy in adults with cyanotic congenital heart disease","volume":"25","author":"Cordina","year":"2015","journal-title":"Cardiol Young"},{"key":"B20","doi-asserted-by":"publisher","first-page":"100632","DOI":"10.1016\/j.ijcha.2020.100632","article-title":"Vascular function in adults with cyanotic congenital heart disease","volume":"30","author":"Tarp","year":"2020","journal-title":"IJC Heart Vasc"},{"key":"B21","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ijcard.2004.08.015","article-title":"Hematological management of the cyanotic adult with congenital heart disease","volume":"97","author":"Oechslin","year":"2004","journal-title":"Int J Cardiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"416","DOI":"10.4070\/kcj.2015.45.5.416","article-title":"Analysis of cardiovascular risk factors in adults with congenital heart disease","volume":"45","author":"Moon","year":"2015","journal-title":"Korean Circ J"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1016\/j.metabol.2010.03.014","article-title":"Serum glucose and lipid levels in adult congenital heart disease patients","volume":"59","author":"Mart\u00ednez-Quintana","year":"2010","journal-title":"Metab Clin Exp"},{"key":"B24","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/s0735-1097(99)00153-9","article-title":"Eisenmenger syndrome in adults: ventricular septal defect, truncus arteriosus, univentricular heart","volume":"34","author":"Niwa","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.atherosclerosis.2014.05.927","article-title":"A decrease in total bilirubin predicted hyper-LDL cholesterolemia in a health screening population","volume":"235","author":"Oda","year":"2014","journal-title":"Atherosclerosis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/157340312801215836","article-title":"Cyanotic congenital heart disease the coronary arterial circulation","volume":"8","author":"Perloff","year":"2012","journal-title":"Curr Cardiol Rev"},{"key":"B27","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.amjcard.2006.01.083","article-title":"Pathogenesis of thrombocytopenia in cyanotic congenital heart disease","volume":"98","author":"Lill","year":"2006","journal-title":"Am J Cardiol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"16","DOI":"10.5551\/jat.RV17010","article-title":"Sphingosine 1-phosphate and atherosclerosis","volume":"25","author":"Kurano","year":"2018","journal-title":"J Atheroscler Thromb"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1531136\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T05:30:33Z","timestamp":1745818233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1531136\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":28,"alternative-id":["10.3389\/fcvm.2025.1531136"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1531136","relation":{},"ISSN":["2297-055X"],"issn-type":[{"type":"electronic","value":"2297-055X"}],"subject":[],"published":{"date-parts":[[2025,4,28]]},"article-number":"1531136"}}